Report from the 25th Annual Western Canadian Gastrointestinal Cancer Consensus Conference on Gastric and Gastroesophageal Cancers, Winnipeg, Manitoba, 26–27 October 2023
Authors:
- Ralph WongRWRalph Wong
- Brady AndersonBrady Anderson
- Bashir BashirBBBashir Bashir
- Justin BatemanJBJustin Bateman
- Haji ChalchalHCHaji Chalchal
- Janine DaviesJDJanine Davies
- Anahita DehmoobedADAnahita Dehmoobed
- Georgia GellerGGGeorgia Geller
- Abhijit GhoseAGAbhijit Ghose
- Sharlene GillSharlene Gill
- Vallerie GordonVGVallerie Gordon
- Susan GreenSGSusan Green
Open Access
- 7 October 2024
- journal article
- research article
- Published by MDPI AG in Current Oncology
- Vol. 31 (10) , 5987-6006
Abstract
The 25th Annual Western Canadian Gastrointestinal Cancer Consensus Conference (WCGCCC) was held in Winnipeg, Manitoba, on 26–27 October 2023. The WCGCCC is an interactive multidisciplinary conference that was attended by healthcare professionals from across Western Canada (British Columbia, Alberta, and Manitoba) who are involved in the care of patients with gastrointestinal cancer. Surgical, medical, and radiation oncologists; pathologists; oncology nurses; pharmacists; and a family physician in oncology (FPO) participated in presentation and discussion sessions for the purpose of developing the recommendations presented here. This consensus statement addresses current issues in the management of gastroesophageal cancers.Keywords
Funding Information
- Pfizer Canada
- Eisai Canada
- Amgen Canada
- Astellas Pharma Canada
- Incyte
- Merck Canada
- Taiho Pharmaceutical
- Bayer Canada
- Takeda Canada
- Ipsen Biopharmaceuticals
- Organon BioSciences
- F. Hoffman-La Roche
- BeiGene
- Bristol-Myers Squibb Canada
- AstraZeneca Canada
This publication has 67 references indexed in Scilit:
- LBA73 Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN studyAnnals of Oncology, 2023
- Programmed death-ligand 1 (PD-L1) expression in primary gastric adenocarcinoma and matched metastasesJournal of Cancer Research and Clinical Oncology, 2023
- VP1-2023: Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 studyAnnals of Oncology, 2023
- Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2022
- 18F-Fludeoxyglucose–Positron Emission Tomography/Computed Tomography and Laparoscopy for Staging of Locally Advanced Gastric CancerJAMA Surgery, 2021
- A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial☆Annals of Oncology, 2021
- Patients' preferences for treatment after neoadjuvant chemoradiotherapy for oesophageal cancerBritish Journal of Surgery, 2018
- Neoadjuvant treatments for locally advanced, resectable esophageal cancer: A network meta‐analysisInternational Journal of Cancer, 2018
- Introducing laparoscopic total gastrectomy for gastric cancer in general practice: a retrospective cohort study based on a nationwide registry database in JapanGastric Cancer, 2018
- Chemotherapy for advanced gastric cancerCochrane Database of Systematic Reviews, 2017